Pages that link to "Q27472916"

The following pages link to Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection (Q27472916):

Displaying 20 items.

• Relation between viral fitness and immune escape within the hepatitis C virus protease (Q27478333) ‎ (← links)
• Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen (Q31112300) ‎ (← links)
• Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits (Q33887085) ‎ (← links)
• Prediction of T-cell epitopes of hepatitis C virus genotype 5a (Q34896702) ‎ (← links)
• Using HLA-A2.1 Transgenic Rabbit Model to Screen and Characterize New HLA-A2.1 Restricted Epitope DNA Vaccines. (Q34978068) ‎ (← links)
• Development of a hepatitis C virus vaccine (Q35105726) ‎ (← links)
• Hepatitis C virus infection: when silence is deception. (Q35196430) ‎ (← links)
• What can the HLA transgenic mouse tell us about autoimmune diabetes? (Q35878811) ‎ (← links)
• Establishment of a cottontail rabbit papillomavirus/HLA-A2.1 transgenic rabbit model (Q35914337) ‎ (← links)
• Generation of T-cell receptors targeting a genetically stable and immunodominant cytotoxic T-lymphocyte epitope within hepatitis C virus non-structural protein 3. (Q35960524) ‎ (← links)
• High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome (Q36978998) ‎ (← links)
• Generation of human MHC (HLA-A11/DR1) transgenic mice for vaccine evaluation. (Q37135201) ‎ (← links)
• T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates. (Q38758212) ‎ (← links)
• Recognition of endogenously synthesized HLA-DR4 restricted HCV epitopes presented by autologous EBV transformed B-lymphoblastoid cell line. (Q40480099) ‎ (← links)
• Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development. (Q41648212) ‎ (← links)
• A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus. (Q42977884) ‎ (← links)
• Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. (Q42980826) ‎ (← links)
• Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice (Q42992408) ‎ (← links)
• Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity (Q43036305) ‎ (← links)
• An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses (Q43040768) ‎ (← links)